Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19： a meta-analysis
W Wen, C Chen, J Tang, C Wang, M Zhou… - Annals of …, 2022 - Taylor & Francis
Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …
controlled. Although great achievements have been made in COVID-19 research and many …
Molnupiravir and its antiviral activity against COVID-19
L Tian, Z Pang, M Li, F Lou, X An, S Zhu… - Frontiers in …, 2022 - frontiersin.org
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …
Novel investigational anti-SARS-CoV-2 agent ensitrelvir “S-217622”: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of …
Lately, nitrogenous heterocyclic antivirals, such as nucleoside-like compounds, oxadiazoles,
thiadiazoles, triazoles, quinolines, and isoquinolines, topped the therapeutic scene as …
thiadiazoles, triazoles, quinolines, and isoquinolines, topped the therapeutic scene as …
Oral antiviral treatments for COVID-19: opportunities and challenges
The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication
and prevent disease progression to a more severe form. However, the timing of antiviral …
and prevent disease progression to a more severe form. However, the timing of antiviral …
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative review
Broad‐spectrum antiviral agents targeting viral RNA‐dependent RNA polymerase (RdRp)
are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 …
are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 …
Effectiveness of molnupiravir in high-risk patients: a propensity score matched analysis
R Najjar-Debbiny, N Gronich, G Weber… - Clinical infectious …, 2023 - academic.oup.com
Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
Highly sensitive high‐performance thin‐layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and …
Favipiravir, molnupiravir, and ritonavir have been recently approved as the first oral
antivirals for treatment of SARS‐CoV‐2 viral infections. Their combination was reported in …
antivirals for treatment of SARS‐CoV‐2 viral infections. Their combination was reported in …
Pharmacological treatment of COVID-19: an opinion paper
A García-Lledó, J Gómez-Pavón… - Revista Española …, 2021 - pmc.ncbi.nlm.nih.gov
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the
most significant and saving advance against the pandemic. The development of vaccines …
most significant and saving advance against the pandemic. The development of vaccines …
The therapeutic and prophylactic potential of quercetin against COVID-19: An outlook on the clinical studies, inventive compositions, and patent literature
Quercetin is a phenolic flavonol compound with established antioxidant, anti-inflammatory,
and immuno-stimulant properties. Recent studies demonstrate the potential of quercetin …
and immuno-stimulant properties. Recent studies demonstrate the potential of quercetin …
Key considerations during the transition from the acute phase of the COVID-19 pandemic: a narrative review
P Rzymski, M Pokorska-Śpiewak, T Jackowska… - Vaccines, 2023 - mdpi.com
The COVID-19 pandemic has been met with an unprecedented response from the scientific
community, leading to the development, investigation, and authorization of vaccines and …
community, leading to the development, investigation, and authorization of vaccines and …